1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease - Pipeline Review, H2 2020, provides an overview of the Polycystic Kidney Disease (Genetic Disorders) pipeline landscape.
Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Polycystic Kidney Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 3, 3, 11, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively.
Polycystic Kidney Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Polycystic Kidney Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Polycystic Kidney Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Polycystic Kidney Disease (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Polycystic Kidney Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Polycystic Kidney Disease - Overview
- Polycystic Kidney Disease - Therapeutics Development
- Polycystic Kidney Disease - Therapeutics Assessment
- Polycystic Kidney Disease - Companies Involved in Therapeutics Development
- Polycystic Kidney Disease - Drug Profiles
- Polycystic Kidney Disease - Dormant Projects
- Polycystic Kidney Disease - Discontinued Products
- Polycystic Kidney Disease - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Polycystic Kidney Disease, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Polycystic Kidney Disease - Pipeline by AceLink Therapeutics Inc, H2 2020
- Polycystic Kidney Disease - Pipeline by Angion Biomedica Corp, H2 2020
- Polycystic Kidney Disease - Pipeline by ATLAS Molecular Pharma SL, H2 2020
- Polycystic Kidney Disease - Pipeline by Bristol-Myers Squibb Co, H2 2020
- Polycystic Kidney Disease - Pipeline by Camurus AB, H2 2020
- Polycystic Kidney Disease - Pipeline by Chinook Therapeutics Inc, H2 2020
- Polycystic Kidney Disease - Pipeline by DiscoveryBiomed Inc, H2 2020
- Polycystic Kidney Disease - Pipeline by Eloxx Pharmaceuticals Inc, H2 2020
- Polycystic Kidney Disease - Pipeline by Galapagos NV, H2 2020
- Polycystic Kidney Disease - Pipeline by Genzyme Corp, H2 2020
- Polycystic Kidney Disease - Pipeline by GLG Pharma SA, H2 2020
- Polycystic Kidney Disease - Pipeline by Goldfinch Bio Inc, H2 2020
- Polycystic Kidney Disease - Dormant Projects, H2 2020
- Polycystic Kidney Disease - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Polycystic Kidney Disease, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Routes of Administration, H2 2020
- Number of Products by Stage and Routes of Administration, H2 2020
- Number of Products by Molecule Types, H2 2020
- Number of Products by Stage and Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AceLink Therapeutics Inc
- Angion Biomedica Corp
- ATLAS Molecular Pharma SL
- Bristol-Myers Squibb Co
- Camurus AB
- Chinook Therapeutics Inc
- DiscoveryBiomed Inc
- Eloxx Pharmaceuticals Inc
- Galapagos NV
- Genzyme Corp
- GLG Pharma SA
- Goldfinch Bio Inc
- IC-MedTech Inc
- Ipsen SA
- Kadmon Corp LLC
- ManRos Therapeutics
- Mironid Ltd
- NovaTarg Therapeutics Inc
- Palladio Biosciences Inc
- Reata Pharmaceuticals Inc
- Regulus Therapeutics Inc
- XORTX Therapeutics Inc
